Guest guest Posted September 18, 2010 Report Posted September 18, 2010 RAO GA, Pandya PK. Statin therapy improves sustained virologic response among diabetic patients with chronic hepatitis C. Gastroenterology. 2010. http://amedeo.com/p2.php?id=20833169 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available TERRIER B, Saadoun D, Sene D, Scerra S, et al. Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients. Gut. 2010. http://amedeo.com/p2.php?id=20841367 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available MALIK R, Schuppan D. Serum fibrosis markers to predict clinical and histological progression in hepatitis C non-responders. Gut. 2010;59:1312-3. http://amedeo.com/p2.php?id=20833662 & s=hep & pm=3e5d26a0f9107d3 ROOMER R, Hansen BE, Janssen HL, de Knegt RJ, et al. Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2010. http://amedeo.com/p2.php?id=20830784 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available NERI S, Bertino G, Petralia A, Giancarlo C, et al. A Multidisciplinary Therapeutic Approach for Reducing the Risk of Psychiatric Side Effects in Patients With Chronic Hepatitis C Treated With Pegylated Interferon alpha and Ribavirin. J Clin Gastroenterol. 2010. http://amedeo.com/p2.php?id=20838237 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available MANGIA A, Bandiera F, Montalto G, Mottola L, et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol. 2010. http://amedeo.com/p2.php?id=20843575 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available MICHTA ML, Hopcraft SE, Narbus CM, Kratovac Z, et al. Species-specific regions of occludin required for hepatitis C virus cell entry. J Virol. 2010. http://amedeo.com/p2.php?id=20844048 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available WENG L, Hirata Y, Arai M, Kohara M, et al. Sphingomyelin activates hepatitis C virus RNA polymerase in a genotype specific manner. J Virol. 2010. http://amedeo.com/p2.php?id=20844041 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available HELLE F, Vieyres G, Elkrief L, Popescu CI, et al. Role of N-linked glycans in the functions of HCV envelope proteins incorporated into infectious virions. J Virol. 2010. http://amedeo.com/p2.php?id=20844034 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available GYARMATHY VA, Neaigus A, Li N, Ujhelyi E, et al. Infection disclosure in the injecting dyads of Hungarian and Lithuanian injecting drug users who self-reported being infected with hepatitis C virus or human immunodeficiency virus. http://amedeo.com/p2.php?id=20840002 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available Scand J Infect Dis. 2010. MAHER L, White B, Hellard M, Madden A, et al. Candidate hepatitis C vaccine trials and people who inject drugs: Challenges and opportunities. Vaccine. 2010. http://amedeo.com/p2.php?id=20831914 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available GREBELY J, J, Hull P, Hopwood M, et al. Factors associated with specialist assessment and treatment for hepatitis C virus infection in New South Wales, Australia. J Viral Hepat. 2010 Sep 14. doi: 10.1111/j.1365-2893.2010.01370. http://amedeo.com/p2.php?id=20840350 & s=hep & pm=3e5d26a0f9107d3 ABSTRACT available Quote
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.